Blackrock Future Health ETF

Johnson & Johnson Expected to Grow Sales 7% in 2026, Seen as Strong Investment Due to Stable Model and Dividend History

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

Edwards Lifesciences EVP Donald E. Bobo Jr. Sells $1.47M in Shares

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

Nanobiotix Reports 85.7% Response Rate for JNJ-1900 in Lung Cancer Trial Phase II

Gilead Sciences Focuses on HIV Growth and Expands Oncology and Inflammation Pipeline via Acquisitions

Oppenheimer Raises Biogen Price Target to $300, Maintains Outperform Rating

Allworth Financial LP Increases Merck Holdings by 71.4%

Gilead Sciences Prices $3 Billion Senior Unsecured Bond Offering

TD Cowen Reaffirms Buy Rating on Biogen with $215 Price Target

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Biogen Advances Alzheimer's Drug to Late Trials Despite Mid-Stage Failure, Shares Jump 6%

Biogen Announces Positive Phase 2 Results for Ionis Partner Drug Diranersen in Alzheimer's Disease

Biogen announces Alzheimer's drug fails to meet primary endpoint in mid-stage trial

Gilead's Yeztugo Revenues Surged 73% QoQ, Exceeding Market Expectations

Daiwa Securities Downgrades Amgen's Target Price to $390.00

Leerink Partners Raises Johnson & Johnson's Rating and Price Target

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

PILL

The Supreme Court declined to hear appeals from six drugmakers against Medicare's drug price negotiations. This decision is projected to save patients $1.5 billion and Medicare $6 billion in the first year. Ongoing legal challenges in lower courts may lead to future Supreme Court reviews.

Bristol Myers Squibb

Johnson & Johnson

Direxion Pharma & Medical Bull 3X

Supreme Court rejects drugmakers’ bid to halt Medicare price talks

GILD

SBIO

ProShare Advisors LLC increased its stake in Gilead Sciences, Inc. by 39.1% in Q4, acquiring 623,752 shares, bringing its total to 2,217,290 shares valued at $272.15 million. Other institutional investors also adjusted their holdings. Gilead's stock opened at $129.67, with a market cap of $160.99 billion. The company reported $2.03 EPS, exceeding estimates, and announced a quarterly dividend of $0.82 per share.

Market Beat

Gilead Sciences

Gilead Sciences, Inc.

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

VG Health

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares Global Healthcare

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

VanEck Biotech ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD

Johnson & Johnson (NYSE: JNJ) is highlighted as a strong investment choice due to its robust business model, AAA credit rating, and a history of 64 consecutive dividend increases. Despite facing legal challenges and potential government price negotiations, the company is expected to grow sales by 7% year-over-year by 2026. Its diversified portfolio and essential products position it well to navigate economic downturns, making it a reliable option for investors seeking stability.

nasdaq

SPDR S&P Health Equip

iShares US Medical Devices

NVIDIA

Intel

S&P Global

NVIDIA Corporation

Meet the Dividend King With a Higher Credit Rating Than the U.S. Government

Donald E. Bobo Jr., an officer serving as CVP, Strategy/Corp Development, reported sales of common stock on May 15, 2026. The weighted average selling price for the transactions was $82.0732 per share. The total proceeds from the sales were $1,472,678. Following the reported transactions, he directly owned 22,798 shares and indirectly owned 152,725 shares.Reporter NameBobo Donald E JrRelationshipCVP,Strategy/Corp DevelopmentTypeSellAmount$1,472,678SEC FilingForm 4DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

TradingView

Edwards Lifesciences

Edwards Lifesciences CVP, Strategy/Corp Development Sold Shares Worth Over $1.4M

CGEN

Compugen (NASDAQ:CGEN) is on track to report interim progression-free survival data from its MAIA-ovarian study in Q1 2027. The company highlighted its first-quarter 2026 results, emphasizing the significance of 2026 for advancing its lead program, COM701, in ovarian cancer. Compugen also noted progress in partnered programs with AstraZeneca and Gilead, including the rilvegostomig program and GS-0321, respectively, with potential milestone payments and royalties.

Compugen

AstraZeneca PLC

AstraZeneca

Compugen Q1 Earnings Call Highlights

Merck has launched a Hypertension Risk Checker to raise awareness about elevated resting heart rates as a potential cardiovascular risk, coinciding with World Hypertension Day. The initiative aims to encourage proactive heart health management, addressing the fact that 1.4 billion people globally live with high blood pressure, many unaware of their condition. Merck emphasizes the importance of early detection and education in managing heart health, marking four decades of commitment to cardiovascular care in the Gulf region.

Zawya

Merck

Merck KGaA

ZAWYA: Merck marks World Hypertension Day with launch of Hypertension Risk Checker

Edwards Lifesciences VP Daniel Lippis sold 620 shares at $81.14 each, totaling $50,306.80, representing a 1.51% decrease in his holdings. Post-sale, he owns 40,411 shares valued at $3,278,948.54. The transaction was executed under a Rule 10b5-1 plan and disclosed to the SEC.

Edwards Lifesciences (NYSE:EW) VP Sells $50,306.80 in Stock

Gilead Sciences is focusing on its HIV business while expanding its oncology and inflammation pipelines through recent acquisitions. Chief Commercial Officer Johanna Mercier highlighted strong growth in HIV, with key products like Yeztugo and Trodelvy driving performance. Recent acquisitions, including Arcellx and Tubulis, aim to enhance Gilead's capabilities in oncology and inflammation. The company anticipates significant market opportunities, particularly in multiple myeloma and ovarian cancer, while maintaining a strong position with no major loss of exclusivity expected until 2036.

Bank of America

Arcellx

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline

BIIB

Goldman Sachs analyst Salveen Richter has reiterated a Buy rating on Biogen, raising the price target from $238 to $250. This decision is driven by the strong performance of Leqembi, which exceeded revenue expectations in the recent quarter. Factors supporting this outlook include a favorable revenue forecast from Eisai, anticipated catalysts for broader use of biomarkers, and potential new formulations that could enhance treatment options.

- Goldman Sachs analyst Salveen Richter maintains a buy rating on Biogen and raises the target price to $250.00, reflecting confidence in Leqembi's strong performance.  
- Leqembi's recent earnings exceeded expectations and showed robust sales in the U.S., Japan, and China, reinforcing optimism in Alzheimer's treatment growth.  
- Factors supporting this positive outlook include Eisai's revenue forecast for Leqembi, potential approval of new treatments, and enhanced opportunities outside the U.S.

Tip Ranks

Biogen

Goldman Sachs

Eisai Co., Ltd.

GS Hldg R

Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250

Oppenheimer has raised its price target for Biogen (NASDAQ:BIIB) from $275 to $300, maintaining an 'outperform' rating. This suggests a potential upside of 55.47% from the previous close. Other analysts have also adjusted their targets, with a consensus rating of 'Moderate Buy' and an average target of $215.62. Biogen's stock recently traded at $192.97, with a market cap of $28.49 billion and a P/E ratio of 20.67.

Oppenheimer

Wells Fargo

Morgan Stanley

Citigroup

HSBC

HSBC HOLDINGS

Barclays

Apellis Pharma

First Horizon

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

HSBC 5xShortSG241213

HSBC Holdings Plc

FIRST HORIZON CORPORATION 6.50% DEP SHS REP 1/4000 PER PFD SER E

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER C

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER B

FIRST HORIZON CORPORATION DEP SH REP 1/4000 INT NON CUM PFD H WI

FIRST HORIZON CORPORATION DEP SHS REPSTG 1/4000TH PERP PFD SER F

Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, Oppenheimer Analyst Says

Blackrock Future Health ETF(BMED.US)